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Abstract
Background: CD4
+CD25
+FOXP3
+ Regulatory T cells (Treg) play a central role in the immune balance to prevent autoimmune
disease. One outstanding question is how Tregs suppress effector immune responses in human. Experiments in mice
demonstrated that Treg restrict effector T cell (Teff) responses by deprivation of the growth factor IL-2 through Treg
consumption, resulting in apoptosis of Teff.
Principal Findings: In this study we investigated the relevance of Teff apoptosis induction to human Treg function. To this
end, we studied naturally occurring Treg (nTreg) from peripheral blood of healthy donors, and, to investigate Treg function
in inflammation in vivo, Treg from synovial fluid of Juvenile Idiopathic Arthritis (JIA) patients (SF-Treg). Both nTreg and SF-
Treg suppress Teff proliferation and cytokine production efficiently as predicted. However, in contrast with murine Treg,
neither nTreg nor SF-Treg induce apoptosis in Teff. Furthermore, exogenously supplied IL-2 and IL-7 reverse suppression,
but do not influence apoptosis of Teff.
Significance: Our functional data here support that Treg are excellent clinical targets to counteract autoimmune diseases.
For optimal functional outcome in human clinical trials, future work should focus on the ability of Treg to suppress
proliferation and cytokine production of Teff, rather than induction of Teff apoptosis.
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Introduction
CD4
+CD25
+FOXP3
+ regulatory T cells (Treg) are of critical
importance for the maintenance of immune homeostasis, as
numerous experimental mouse models for autoimmune diseases
correlate the presence of functional Tregs with amelioration of
disease severity [1,2]. In humans Treg also play an important role
in the immune balance, as patients lacking functional Treg, due to
loss-of-function mutations in the transcription factor FOXP3,
suffer from severe generalized autoimmune disease; immune
dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX)
[3,4]. In addition, in human autoimmune diseases, like Juvenile
Idiopathic Arthritis (JIA), negative correlations are found between
the presence of regulatory T cells and disease severity[5].
Therefore, Treg are considered an important therapeutic target
for a large range of human immune mediated diseases, and
ongoing clinical trials attempt to modulate the population of Treg,
and thereby restore immune balance. For example, in diabetes
mellitus type 1, patients were treated with anti-CD3 antibodies in
order to enhance Treg function, which resulted in clinical
improvement and increased residual b-cell function[6,7]. More-
over, in a clinical trial for cord blood transplantation in patients
suffering from haematological cancer, infusion of donor-derived
Treg is tested to prevent or reduce Graft versus Host Disease
(GvHD) (NCT00602693, www.clinicaltrials.gov).
Despite these potentially far-reaching applications of Tregs in
humans, questions remain with regard to the underlying
mechanisms of Treg action, particularly in humans. Tregs may
suppress effector cells either through cell-cell contact, the
production of suppressive cytokines, and/or through the con-
sumption of cytokines and growth factors such as IL-2 [8]. It is
clear that IL-2 in many aspects is crucial for Treg function [9,10].
For one, it is required for Treg expansion, and regulates FOXP3
expression [11,12], and it is also indispensable for Treg mediated
suppression [13]. On the other hand, FOXP3 suppresses IL-2
transcription, by binding to the IL-2 promoter [14,15]. As a result
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7183Treg do not produce IL-2, and even may act as a ‘sink’ for IL-2.
Thus, competition for IL-2 between effector T cells (Teff) and
Treg, which express a higher level of IL-2Ra chain (CD25)
compared to Teff, may counteract proliferation of Teff [16,17].
Accordingly, Pandiyan et al. recently showed that in mice Treg
consume IL-2 and thereby induce apoptosis in the Teff population
[18,19]. This mechanism of apoptosis through cytokine depriva-
tion was responsible for the suppressive function of Treg.
Consistently, IL-2 and other IL-2Rc-chain binding cytokines,
such as IL-7, were able to overcome cell death [18], and, in earlier
reports, have been shown to interfere with both murine and
human Treg-mediated suppression [17,20].
We aimed to determine whether apoptosis induction via
cytokine consumption by Treg is an important mechanism for
human Treg-mediated suppression of Teff. As it is not fully
understood how human Treg mediate their suppressive action on
Teff, we studied the suppressive capacity and induction of
apoptosis by naturally occurring Treg from peripheral blood and
compared it to, assumedly in vivo activated Treg from an
inflammatory site, the synovial fluid, of JIA patients. Our findings
demonstrate that apoptosis induction in Teff is not important for
human Treg mediated suppression.
Results
nTreg are highly suppressive without inducing apoptosis
in Teff
We first established that human Treg inhibit proliferation of
activated Teff. CFSE labeled Teff were co-cultured for 5 days with
a graded amount of CD4
+CD25
+CD127
low naturally occurring
Treg (nTreg), in 200 ml culture medium, and suppression of Teff
proliferation and induction of Teff apoptosis were determined. As
expected, nTreg inhibited proliferation of Teff, as measured by
decreased CFSE dilution in Teff cells (Figure 1A). This
suppression of proliferation increased with titrated amounts of
Treg in the culture, in a dose-dependent manner (Figure 1B).
Next, cells from the same co-cultures were stained with 7-AAD
and Annexin V and gated on CFSE+ cells (See Figure S1A, B) to
determine apoptosis in Teff. Only few apoptotic cells were found
in cultures with Teff only, and the percentage of apoptotic cells did
not increase upon the presence of more nTreg (Figure 1C, D),
which was similar for the absolute number of apoptotic cells
(Figure 1E). Thus under normal culture conditions, human nTreg
do not induce apoptosis in Teff, while efficiently suppressing Teff
proliferation.
We hypothesized that if cytokine consumption by Treg in the
vicinity is responsible for apoptosis in Teff, culture of the same
number of Teff and Treg in a smaller volume should enhance
suppression mediated by apoptosis induction. Therefore, all
further cultures were performed in 75 ml instead of 200 ml
medium. Under these conditions the level of suppression was
higher (up to 65% average at a 1-1 ratio) compared to normal
culture conditions (up to 48% average at a 1-1 ratio) (Figure 1F).
Furthermore, a larger number of Teff became apoptotic (up to 750
Annexin V
+7-AAD
+ cells average for Teff+Teff ) (Figure 1H), but
in the co-cultures with nTreg the percentage of apoptotic cells only
slightly increased (Figure 1G), and the number of apoptotic Teff
even decreased (Figure 1H). Although we show a low upregulation
of Annexin V on highly activated cells (Figure S3A), the level of
apoptosis per cell division was independent of the presence of Treg
(Figure S5). To establish that day 5 was the appropriate timepoint
to measure apoptosis in our assays, we also measured cell death on
day 3 and 4. Consistently, on day 3 and 4 hardly any apoptosis was
seen (Figure S1C, D). Furthermore, we show that Teff in our assay
are able to go into apoptosis, by titrating Sheath Fluid (BD
Biosciences), containing ethanol into cultures with Teff (Figure
S2A, B), causing Teff apoptosis in a dose-dependent manner.
Thus, apoptosis induction does not occur in Teff + nTreg co-
cultures, whereas high levels of suppression are reached.
Altogether, these data clearly demonstrate that apoptosis induction
is not important for nTreg mediated suppression.
IL-2 and IL-7 overcome suppression, without influencing
apoptosis
In mice, cytokine consumption was suggested to be pivotal for
Treg-mediated apoptosis in Teff and suppression. Therefore, we
investigated whether absence of IL-2Rc-chain binding cytokines
plays a role in the induction of apoptosis in Teff and suppression
by human nTreg. In co-cultures of Teff and nTreg we observed a
clear decrease in IL-2, as well as other cytokines important for Teff
function; IL-5, IL-13, IL-10, IFNc, TNFa, but not IL-17
(Figure 2A, C (upper panel)). This lack of IL-17 suppression could
be due to a resistance of Th17 cells to Treg mediated suppression
[21,22] The decrease of cytokines in the culture medium in the
presence of Treg could be due to either a general suppression of
Teff cytokine production, or to cytokine consumption.
To investigate this further, we studied whether exogenously
added cytokines could affect apoptosis induction of Teff, or
suppression of proliferation and cytokine production by Teff.
When high concentrations of exogenous IL-2 or IL-7 were added,
the proliferation of Teff cells increased (data not shown).
Furthermore, suppression of Teff proliferation was abrogated in
all co-culture ratios (Figure 2B), which is in line with studies
describing abrogation of Treg mediated suppression by IL-2 and
IL-7, by either Teff stimulation, or, in case of IL-2, abrogation of
Treg anergy [17,20,23–25]. The high levels of IL-2 or IL-7
abrogated nTreg-mediated suppression of cytokine production by
Teff as well (Figure 2C and Table S1). Furthermore, it seems that
both IL-2 and IL-7 increase cytokine production of Treg, which
may have contributed to abrogation of suppression. In contrast,
although the percentage of apoptotic cells seems to decrease
(Figure 2D and Figure S3B), IL-2 and IL-7 did not decrease
numbers of apoptotic Teff in co-cultures, instead the number of
apoptotic cells was even significantly increased (Figure 2E) Thus,
IL-2Rc-chain binding cytokines prevent suppression of Teff
proliferation and cytokine production, but this is not accompanied
by a reduction in apoptosis. Although we cannot conclude from
these data whether cytokine consumption is involved, this
emphasizes that nTreg mediated suppression is independent of
apoptosis induction in Teff.
Apoptosis induction in Teff is irrelevant for Treg function
in inflammation
Last, we wished to establish the relevance of our findings on
nTreg to human Treg function in ongoing inflammation.
Therefore, we studied Treg from within a chronically inflamed
environment, the synovial fluid of JIA patients (SF-Treg). In
synovial fluid, Treg are abundantly present and highly activated,
due to the chronic inflammation. Furthermore, Teff from the SF
probably have a different activation state, which may be
contributing to the ongoing inflammation in JIA. To make a
reliable comparison between Treg from the peripheral blood and
Treg from the site of inflammation, it is preferable to use the same
Teff population in all assays. Therefore, we co-cultured SF-Treg
with Teff obtained from peripheral blood of the same patient in
75 ml medium. Probably due a different cellular composition,
which may be caused by contaminating activated T cells,
Human Treg Cause No Teff Death
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e7183Figure 1. Naturally occurring Treg suppress Teff proliferation, but do not induce apoptosis. Cells were cultured in 200 ml medium for 5
days (n=3). (A) Proliferation of Teff measured by flow cytometry, cultured alone (left) or in co-culture with naturally occurring Treg (1-1) (right).1
representative example is shown. (B) Level of suppression of Teff proliferation, calculated for several ratios of Teff + Treg, and Teff + Teff (ratio 1-1),
compared to culture of Teff alone (suppression=0%). (C) Apoptotic Teff cells (CFSE
+) were measured after 7-AAD and Annexin V staining by flow
cytometry analysis. Percentage of apoptosis in Teff cultured alone (left) and in co-culture with Treg (1-1) (right). 1 representative example is shown.
(D) Average percentage, and (E) absolute number, corrected for cell input, of apoptotic Teff expressing 7-AAD and Annexin V, for several co-culture
ratios of Teff + Treg, Teff + Teff (1-1) and Teff alone,. Cells were cultured in 75 ml medium for 5 days (n=9). (F) Level of suppression of Teff
proliferation, calculated for several ratios of Teff + Treg, and Teff + Teff (ratio 1-1), compared to culture of Teff alone (suppression=0%). (G) Average
percentage, and (H) absolute number, corrected for cell input, of apoptotic Teff cells expressing 7-AAD and Annexin V, for several co-culture ratios of
Teff + Treg, Teff + Teff and Teff alone (n=9). Error bars represent means6s.e.m., * P,0.05, # P,0.01, $ P,0.001.
doi:10.1371/journal.pone.0007183.g001
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PLoS ONE | www.plosone.org 3 September 2009 | Volume 4 | Issue 9 | e7183Figure 2. Exogenous IL-2 and IL-7 decrease suppression of Teff proliferation and cytokine production, but do not decrease
apoptosis. Cells were cultured in 75 ml medium for 5 days (A) Levels of cytokines, present in culture medium, on day 5 of culture, in several co-
culture ratios of Teff + Treg, Teff + Teff (1-1), and Teff alone (n=9). (B) Level of suppression of CFSE
+ Teff proliferation, calculated for several ratios of
Teff + Treg, Teff + Teff (1-1) and Teff alone (suppression=0%), cultured without (black bars), or with IL-2 (white bars) or IL-7 (grey bars). Suppression
was calculated by comparing co-cultures with Teff alone with equal cell culture conditions. (C) Mean levels of cytokines, present in culture medium
on day 5 of culture, in medium (-), with addition of IL-2 (IL-2) or IL-7 (IL-7). A color profile of the means was made to show the differences between
culture conditions (see also Table S1). (D) Average percentage, and (E) absolute number, corrected for cell input,of apoptotic CFSE
+ Teff cells,
expressing 7-AAD and Annexin V, in several co-culture ratios of Teff + Treg and Teff alone, cultured without or with IL-2 or IL-7. (B–E, n=5). Error bars
represent means6s.e.m., * P,0.05, # P,0.01, $ P,0.001.
doi:10.1371/journal.pone.0007183.g002
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nTreg (Figure 3A, B), whereas suppression of Teff cytokine
production was similar to nTreg (Figure 3C, D, see also Tables S2
and S3). Still, similar as for nTreg, despite a slight increase of the
percentage of apoptotic cells, a decreased number of apoptotic
Teff was found in the presence of SF-Treg (Figure 3E, F).
Altogether, even Treg from an inflammatory environment do not
induce apoptosis in Teff cells to achieve suppression of Teff
proliferation and cytokine production.
Discussion
Pivotal studies in mice models have pointed out that Treg are
indispensable for the maintenance of peripheral immune tolerance.
Also in humans a similar role of Tregs is likely, prompting
discussions about their clinical applicability. Though comparable in
many aspects, several differences between mouse and human Treg
phenotype, function and mechanisms of suppression have been
identified in the past few years. For instance, the expression of
FOXP3 seemsto be a more consistent markerfor functional Treg in
mice, than it is in humans [26–28]. As for mechanisms of
suppression, IL-35 production by Treg is important for suppression
in mice [29],while IL-35 is not even expressedby humanTreg [30].
Since Treg are currently tested for therapeutic applications in
humans, it is especially important to determine to what extend
results obtained in mice can be translated to human Treg.
Recently, Pandiyan et al. exemplified a new mechanism of
action of Treg in mice, namely their capacity to induce apoptosis
in Teff, based on specific cytokine consumption as Treg can
consume IL-2 produced by the Teff. Also, addition of IL-2 to co-
cultures of Teff and Treg prevented the apoptosis of Teff. Though
they did not directly show that addition of IL-2Rc-chain binding
cytokines, which diminished apoptosis, also prevented suppression
in vitro, in vivo they did find that induction of Teff apoptosis is
indeed important for Treg function. Furthermore, previous reports
show that suppression in vitro by murine Treg is prevented by
addition of IL-2Rc-chain binding cytokines [17]. Our current data
show some similarities between the mouse and human system, but
also reveal an essential difference between mouse and human
Tregs; human Treg function is not mediated by apoptosis of Teff.
Obviously, human experiments such as these are restricted to in
vitro assays, and only limited numbers of cells are available.
However, in vitro Treg assays, similar to those used for mice, can be
performed with human cells as well and compared to data
obtained in experimental models.
Similar to mice, we show that naturally occurring human Treg
very efficiently suppress both proliferation and cytokine produc-
tion by effector T cells, which can be reversed by addition of IL-
2Rc-chain binding cytokines. These results are consistent with
earlier reports on human and murine Treg which show both
inhibition of Teff IL-2 mRNA production, as well as Teff
proliferation by Treg, and a decrease of suppression of Teff
proliferation by addition of high levels of exogenous IL-2
[17,31,32]. Also, Treg derived from a highly inflammatory
environment, synovial fluid from the joints of JIA patients,
suppress Teff proliferation and cytokine production. Obviously,
mouse splenocytes differ in many aspects from human PBMC
[33]. Here we show that human Teff seem to be less prone to
apoptosis than mouse Teff. When comparing cell death in cultures
with only Teff, human Teff show hardly any apoptosis (2%),
whereas mouse Teff show a higher level of apoptotic cells (20%)
[18]. And, importantly, we show that suppression by human Treg
does not involve induction of apoptosis in Teff: the absolute
numbers of apoptotic cells decrease in the presence of Treg.
IL-2 is an important cytokine for Treg function, both in mice
and humans. However, we do not find a decrease of apoptosis in
Teff upon addition of IL-2. This may again be due to the low level
of apoptosis in Teff in general. However, it could also be explained
by the fact that Teff do not necessarily require IL-2 to survive or
become activated. This is confirmed by recent data obtained by in
vitro tests on peripheral blood cells from a specific group of IPEX
patients. In these patients Teff produce only low levels of IL-2 and,
remarkably, the deficit in Treg function can be overcome by
addition of IL-2 to cell cultures. Thus, the in vivo lack of Treg
function could be explained by the decreased production of IL-2
by Teff in these IPEX patients [3,34].Altogether, this suggests that
in humans IL-2 is very important for Treg function, but is not
required for Teff survival and function, as these Teff, despite low
IL-2 production, are still highly activated and causing disease.
We show here, in line with earlier publications, that addition of
IL-2 and IL-7 abrogates suppression of both Teff proliferation and
cytokine production. This could be due to a higher activation of
the Teff, as the Teff cultured alone proliferate more and produce
more cytokines in the presence of IL-2 and IL-7, or, in case of IL-
2, to abrogation of Treg anergy. In addition, we do not find a
decrease of the added IL-2 in these cultures with Treg present.
This suggests that IL-2 is not consumed by the Treg, although we
can not exclude that the level of exogenous IL-2 is simply too high
to detect consumption by Treg.
In conclusion, we here point out an important difference
between human and murine Treg function: human Treg do not
induce apoptosis in Teff to achieve suppression. With these data
we emphasize that experimental data from mouse models should
be carefully validated in human cells to identify discrepancies, and
to ensure that further therapeutic applications are efficient and
safe. This does not mean that Treg are less valuable targets for
intervention. It could even be argued that if human Treg, instead
of eliminating Teff by inducing apoptosis, render Teff either
anergic, or even turn them into suppressor cells themselves
[35,36], may be able to exert a stronger bystander suppression in
an ongoing inflammatory response.
Our functional data here support that Treg are excellent clinical
targets to counteract autoimmune diseases. For optimal functional
outcome in human clinical trials, future work should focus on the
ability of Treg to suppress proliferation and cytokine production of
Teff, rather than induction of Teff apoptosis.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the UMC Utrecht. All patients
provided written informed consent for the collection of samples
and subsequent analysis.
Cells, medium and reagents
Peripheral blood mononuclear cells (PBMC) were isolated from
peripheral blood of healthy volunteers and JIA patients and
synovial fluid mononuclear cells (SFMC) from the synovial fluid of
JIA patients, after informed consent, using Ficoll Isopaque density
gradient centrifugation (Amersham Biosciences, NJ, USA). RPMI
1640 containing 10 mM HEPES (Seromed), 2 mM L-glutamine
100 U/ml penicillin-streptomycin and 10% human AB serum was
used as culture medium (all Invitrogen, Carlsbad, USA). Where
indicated, IL-2 (1000 U/ml (=60 ng/ml), Chiron, Uxbridge, UK)
or IL-7 (10 ng/ml, PeproTech Inc, Rocky Hill, NJ, USA), were
added.
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PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e7183Figure 3. Synovial fluid-derived Treg suppress Teff proliferation and cytokine production, but do not induce apoptosis. Cells were
cultured in 75 ml medium for 5 days. (A) Proliferation of CFSE
+ Teff measured by flow cytometry, cultured alone (left) or in co-culture with SF-Treg (1-
1) (right). 1 representative example is shown. (B) Level of suppression of CFSE
+ Teff proliferation, calculated for several ratios of Teff + SF-Treg, and
Teff + Teff (1-1), compared to culture of Teff alone (suppression=0%). (C) Levels of cytokines, present in culture medium, on day 5 of culture, in
several co-culture ratios of Teff + SF-Treg, Teff + Teff (1-1) and Teff alone. (D) Mean levels of cytokines, present in culture medium on day 5 of culture.
A color profile of the means was made to show the differences between culture conditions (see also Table S2). (E) Average percentage, and, (F)
absolute number, corrected for cell input, of apoptotic CFSE
+ Teff for several co-culture ratios of Teff + SF-Treg, Teff + Teff (1-1) and Teff alone (B–E,
n=3). Error bars represent means6s.e.m.
doi:10.1371/journal.pone.0007183.g003
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CD4
+ CD25
2 effector T cells (Teff), were magnetically isolated
from PBMC using a CD4 T Lymphocyte Enrichment Set (BD
Biosciences). Subsequently, CD25
+ T cells were depleted using
CD25 Magnetic Particles (BD Biosciences). All magnetic cell
isolations were performed according to the manufacturer’s
instructions. The CD4
+CD25
2 T cells were labeled with 3 mM
CFSE for 10 min at 37uC and extensively washed. 25,000 Teff
(Teff) were plated into anti-CD3-coated wells (OKT-3, 1.5 mg/
ml), and to control for higher cell numbers in co-cultures
(crowdedness) 50,000 Teff were plated (Teff+Teff).
CD4
+CD25
+CD127
2 T cells were sorted as Treg from PBMC
[37,38] (with an average of 58% FOXP3
+ cells613% s.d.) or
SFMC [39] (with an average of 24% FOXP3
+ cells612% s.d.) by
FACS Aria (BD Biosciences) and added in different ratios to Teff.
T cell depleted, irradiated autologous PBMC (3500 Rad) were
used as Antigen presenting cells (APC), 30,000 per well. Cells were
cultured for 5 days and proliferation was measured by flow
cytometry on a FACS Calibur (BD Biosciences). The levels of
FOXP3
+ cells in the CD4
+CD25
+CD127
low T cells directly
isolated from PBMC or SFMC were lower than expected. This is
due to an underestimation of the percentage of FOXP3
+ cells (See
Figure S4). All data were analyzed using Cellquest software.
Flow cytometry staining
To determine levels of apoptosis, cells were stained with
Annexin V PE and 7-AAD, using a staining kit according to the
manufacturer’s instructions (all BD Biosciences). CFSE
+ cells were
gated to determine cell death within the Teff population. For
FOXP3 analysis, PBMC were washed twice in FACS buffer (PBS
containing 2% FCS and 0.1% sodium azide), adjusted to
0.521610
6 cells/ml in FACS buffer and blocked with mouse
serum (5 min at 4uC). Subsequently, the cells were incubated in
50 ml FACS buffer containing three appropriately diluted PE,
FITC or PerCP labeled mAbs against human CD4 (clone RPA-
T4), CD25 (clone 2A3), CD127 (clone hIL-7R-m21), all from BD
Biosciences. For intranuclear staining of APC or Pacific Blue
FOXP3 (clone PCH101), V450 FOXP3 (clone 259D, BD
Bioscience) or Isotype Control, the cells were first surface stained,
then fixed, permeabilized and stained using the FOXP3 staining
kit (eBioscience) according to the manufacturer’s instructions. Cells
were analyzed on a FACS Calibur (BD Biosciences). All data were
analyzed using Cellquest software.
Analysis of cytokine production by multiplexed particle-
based flow cytometric assay
Cell culture supernatants were collected, stored at 280uC and
processed within 1 month. Cytokine concentrations were mea-
sured with the Bio-Plex system in combination with the Bio-Plex
Manager software, version 4.0 (Bio-Rad Laboratories, Hercules,
CA, USA), which employs the Luminex xMAP technology as
previously described [40]. The following cytokines were measured:
IL-2, IL-5, IL-7, IL-10, IL-13, IL-17, tumor necrosis factor-a
(TNF-a), and interferon-c (IFNc).
Statistical analysis
For statistical analysis of multiple groups One-way ANOVA or
nonparametric ANOVA; Kruskal-Wallis test, were used. Bonfer-
roni or Dunn’s Multiple Comparison Test post test were used, to
compare between 2 selected groups. To compare between two
groups, non-parametric T-test, Mann Whitney was used. P values
below 0.05 were considered significant.
Supporting Information
Table S1 IL-2 and IL-7 inhibit nTreg mediated suppression of
Teff cytokine production, but nTreg do not consume IL-2 or IL-7.
Found at: doi:10.1371/journal.pone.0007183.s001 (0.06 MB
PDF)
Table S2 SF-Treg suppress Teff cytokine production.
Found at: doi:10.1371/journal.pone.0007183.s002 (0.03 MB
PDF)
Table S3 The level of cytokine suppression for nTreg and SF-
Treg.
Found at: doi:10.1371/journal.pone.0007183.s003 (0.01 MB
PDF)
Figure S1 Proliferation and apoptosis of Teff after 3, 4, and 5
days of culture in the presence and absence of Treg. (A) Gated
CFSE+ Teff in the presence of APC (left plot) or APC + Treg
(middle plot) after 5 days of culture. For comparison, Treg only +
APC are shown as well (right plot). 1 representative example of
n=9. (B) Gated CFSE+ Teff in the presence of APC (left plot) or
APC + Treg (right plot) after 3 days of culture. For comparison,
Treg only + APC are shown as well (right plot). 1 representative
example of n=3. (C) Average percentage, and (D) absolute
number (corrected for cell input) of apoptotic Teff, expressing 7-
AAD and Annexin V, for several co-culture ratios of Teff + Treg,
Teff + Teff and Teff alone after 3 (black bars), 4 (white bars) or 5
days (grey bars) of culture (n=3). Error bars represent means A ˆ6
s.e.m.
Found at: doi:10.1371/journal.pone.0007183.s004 (1.66 MB TIF)
Figure S2 Sheath Fluid, containing ethanol, dose dependently
induces apoptosis in Teff. (A) Percentage of apoptotic Teff,
expressing 7-AAD and Annexin V, after culture for 5 days without
(left panel) or with increasing amounts of PBS as a control (middle
panel) or Sheath Fluid to induce apoptotic cells (right panel). 1
representative of n=2. (B) Average percentage of apoptotic Teff,
expressing 7-AAD and Annexin V, for increasing concentrations
of PBS (white bars) and Sheath Fluid (black bars) (n=2). Error
bars represent means A ˆ6 s.e.m.
Found at: doi:10.1371/journal.pone.0007183.s005 (1.08 MB TIF)
Figure S3 Annexin V expressing Teff and apoptotic Teff,
expressing both Annexin V and 7-AAD, in the presence and
absence of IL-2 and IL-7. (A) Annexin V expression of gated
CFSE+ Teff cultured for 5 days without additional stimuli (left
panel), in the presence of 20% Sheath Fluid to induce apoptotic
cells (middle panel), or in the presence of IL-2 or IL-7 (right panel).
1 representative example for each condition is shown. (B)
Percentage of apoptotic Teff, expressing 7-AAD and Annexin V,
alone or in the presence of Treg (1-1) in the absence (left panel) or
presence of IL-2 (middle panel) or IL-7 (right panel). 1
representative example of n=5.
Found at: doi:10.1371/journal.pone.0007183.s006 (1.63 MB TIF)
Figure S4 Percentage of FOXP3 expressing cells within the
CD4+CD25+CD127low Treg population. (A) CD25 and CD127
expression of gated CD4+ T cells. The gate used for sorting the
CD4+CD25+CD127low Treg population is indicated. For
comparison of FOXP3 expression CD4+CD25- cells were gated.
1 representative example is shown. (B) FOXP3 expression
measured by different FOXP3 antibodies within the
CD4+CD25+CD127 low Treg population (left panel), within the
CD4+CD25- cells (middle panel), and corresponding isotype
controls gated on CD4+CD25+CD127low Treg (right panel). 1
representative example of n=4.
Found at: doi:10.1371/journal.pone.0007183.s007 (0.91 MB TIF)
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Teff, expressing both Annexin V and 7-AAD, in the presence and
absence of Treg. (A) Total cells expressing AnnexinV (left panel)
and 7-AAD (right panel), in the presence and absence of Treg at
day 5 of culture. 1 representative example of n=9. (B) Total cells
expressing AnnexinV (left panel) and 7-AAD (right panel), in the
presence and absence of Treg at day 3 of culture. 1 representative
example of n=3. (C) Average absolute number of apoptotic Teff,
expressing 7-AAD and Annexin per cell division (0=undivided
cells), in the absence (black bars) and presence (white bars) of Treg
at day 5 of culture. (n=4) Error bars represent means A ˆ6 s.e.m.
Found at: doi:10.1371/journal.pone.0007183.s008 (1.97 MB TIF)
Acknowledgments
The authors wish to thank Mariska van Dijk for her technical assistance in
the multiplexed particle-based flow cytometric assays, Gerdien Mijnheer
and Eveline Delemarre for technical assistance in in vitro assays, Mark Klein
for cell sorting, Nico Wulffraat and Bas Vastert for inclusion of JIA
patients, and Femke van Wijk, Marianne Boes and Paul Coffer for critically
reading the manuscript.
Author Contributions
Conceived and designed the experiments: YV EJW NHvT JB BJP.
Performed the experiments: YV EJW NHvT WdJ. Analyzed the data: YV
EJW NHvT WdJ. Wrote the paper: YV EJW JB BJP.
References
1. You S, Leforban B, Garcia C, Bach JF, Bluestone JA, et al. (2007) Adaptive
TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a
privileged target of anti-CD3 antibody treatment. ProcNatlAcadSciUSA 104:
6335.
2. Rodriguez-Palmero M, Franch A, Castell M, Pelegri C, Perez-Cano FJ, et al.
(2006) Effective treatment of adjuvant arthritis with a stimulatory CD28-specific
monoclonal antibody. JRheumatol 33: 110.
3. Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, et al. (2006) Defective
regulatory and effector T cell functions in patients with FOXP3 mutations.
JClinInvest 116: 1713.
4. Le BS, Geha RS (2006) IPEX and the role of Foxp3 in the development and
function of human Tregs. JClinInvest 116: 1473.
5. de Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, et al. (2004)
CD4+CD25(bright) regulatory T cells actively regulate inflammation in the
joints of patients with the remitting form of juvenile idiopathic arthritis.
J Immunol 172: 6435.
6. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L,
et al. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1
diabetes. N Engl J Med 352: 2598–2608.
7. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, et al. (2002)
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
N Engl J Med 346: 1692–1698.
8. Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work.
Nat Rev Immunol 8: 523–532.
9. Brandenburg S, Takahashi T, de la Rosa M, Janke M, Karsten G, et al. (2008)
IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells.
Eur J Immunol 38: 1643–1653.
10. Scheffold A, Huhn J, Hofer T (2005) Regulation of CD4+CD25+ regulatory T
cell activity: it takes (IL-)two to tango. Eur J Immunol 35: 1336–1341.
11. Setoguchi R, Hori S, Takahashi T, Sakaguchi S (2005) Homeostatic
maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by
interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.
J Exp Med 201: 723–735.
12. D’Cruz LM, Klein L (2005) Development and function of agonist-induced
CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat
Immunol 6: 1152–1159.
13. Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ (2002)
Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J Exp
Med 196: 851–857.
14. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, et al. (2006) IL-2
regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through
a STAT-dependent mechanism and induces the expansion of these cells in vivo.
Blood 108: 1571.
15. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA (2007) IL-2 is essential for
TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T
cells and for expansion of these cells. J Immunol 178: 2018–2027.
16. Maloy KJ, Powrie F (2005) Fueling regulation: IL-2 keeps CD4+ Treg cells fit.
Nat Immunol 6: 1071–1072.
17. de la Rosa M, Rutz S, Dorninger H, Scheffold A (2004) Interleukin-2 is essential
for CD4+CD25+ regulatory T cell function. Eur J Immunol 34: 2480–2488.
18. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ (2007)
CD4(+)CD25(+)Foxp3(+) regulatory T cells induce cytokine deprivation-
mediated apoptosis of effector CD4(+) T cells. NatImmunol 8: 1353.
19. Scheffold A, Murphy KM, Hofer T (2007) Competition for cytokines: T(reg)
cells take all. Nat Immunol 8: 1285–1287.
20. van Amelsfort JM, van Roon JA, Noordegraaf M, Jacobs KM, Bijlsma JW, et al.
(2007) Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory
T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum 56:
732–742.
21. Stummvoll GH, DiPaolo RJ, Huter EN, Davidson TS, Glass D, et al. (2008)
Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in
pathological pattern and in susceptibility to suppression by regulatory T cells.
J Immunol 181: 1908–1916.
22. Chauhan SK, El Annan J, Ecoiffier T, Goyal S, Zhang Q, et al. (2009)
Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression.
J Immunol 182: 1247–1252.
23. Koenen HJ, Fasse E, Joosten I (2003) IL-15 and cognate antigen successfully
expand de novo-induced human antigen-specific regulatory CD4+ T cells that
require antigen-specific activation for suppression. J Immunol 171: 6431–6441.
24. Earle KE, Tang Q, Zhou X, Liu W, Zhu S, et al. (2005) In vitro expanded
human CD4+CD25+ regulatory T cells suppress effector T cell proliferation.
Clin Immunol 115: 3–9.
25. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M (2004)
Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory
T cells. Blood 104: 895–903.
26. Wang J, Ioan-Facsinay A, van dV, Huizinga TW, Toes RE (2007) Transient
expression of FOXP3 in human activated nonregulatory CD4(+) T cells.
EurJImmunol 37: 129.
27. Ziegler SF (2006) FOXP3: of mice and men. Annu Rev Immunol 24: 209–226.
28. Tran DQ, Ramsey H, Shevach EM (2007) Induction of FOXP3 expression in
naive human CD4+FOXP3 T cells by T-cell receptor stimulation is
transforming growth factor-beta dependent but does not confer a regulatory
phenotype. Blood 110: 2983.
29. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, et al. (2007) The
inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450:
566–569.
30. Bardel E, Larousserie F, Charlot-Rabiega P, Coulomb-L’Hermine A,
Devergne O (2008) Human CD4+ CD25+ Foxp3+ regulatory T cells do not
constitutively express IL-35. J Immunol 181: 6898–6905.
31. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) Cutting edge:
IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell
suppressor function. J Immunol 172: 6519–6523.
32. Oberle N, Eberhardt N, Falk CS, Krammer PH, Suri-Payer E (2007) Rapid
suppression of cytokine transcription in human CD4+CD25 T cells by
CD4+Foxp3+ regulatory T cells: independence of IL-2 consumption, TGF-
beta, and various inhibitors of TCR signaling. J Immunol 179: 3578–3587.
33. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse
and human immunology. J Immunol 172: 2731–2738.
34. Roncarolo MG, Gregori S (2008) Is FOXP3 a bona fide marker for human
regulatory T cells? Eur J Immunol 38: 925–927.
35. Qiao M, Thornton AM, Shevach EM (2007) CD4+ CD25+ [corrected]
regulatory T cells render naive CD4+ CD25- T cells anergic and suppressive.
Immunology 120: 447–455.
36. Zanin-Zhorov A, Cahalon L, Tal G, Margalit R, Lider O, et al. (2006) Heat
shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate
TLR2 signaling. JClinInvest 116: 2022.
37. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, et al. (2006) CD127
expression inversely correlates with FoxP3 and suppressive function of human
CD4+ T reg cells. J Exp Med 203: 1701–1711.
38. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, et al. (2006)
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human
regulatory and activated T cells. JExpMed 203: 1693.
39. Raghavan S, Cao D, Widhe M, Roth K, Herrath J, et al. (2008) FOXP3
expression in blood, synovial fluid and synovial tissue during inflammatory
arthritis and intra-articular corticosteroid treatment. Ann Rheum Dis.
40. de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, et al.
(2007) Blood and synovial fluid cytokine signatures in patients with juvenile
idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 66: 589–598.
Human Treg Cause No Teff Death
PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e7183